Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Neglect, HPA axis reactivity, and development.

Reilly EB, Gunnar MR.

Int J Dev Neurosci. 2019 Jul 30. pii: S0736-5748(19)30055-3. doi: 10.1016/j.ijdevneu.2019.07.010. [Epub ahead of print] Review.

PMID:
31374220
2.

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K.

J Clin Oncol. 2018 Nov 20;36(33):3298-3306. doi: 10.1200/JCO.2018.78.7697. Epub 2018 Oct 4. Erratum in: J Clin Oncol. 2019 Jan 20;37(3):261.

PMID:
30285518
3.

Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, Fischer JS, Chu KL, Ames WW, Mittapalli RK, Lee HJ, Zeng J, Roberts-Rapp LA, Loberg LI, Ansell PJ, Reilly EB, Ocampo CJ, Holen KD, Tolcher AW.

Cancer. 2018 May 15;124(10):2174-2183. doi: 10.1002/cncr.31304. Epub 2018 Mar 13.

4.

Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.

Phillips AC, Boghaert ER, Vaidya KS, Falls HD, Mitten MJ, DeVries PJ, Benatuil L, Hsieh CM, Meulbroek JA, Panchal SC, Buchanan FG, Durbin KR, Voorbach MJ, Reuter DR, Mudd SR, Loberg LI, Ralston SL, Cao D, Gan HK, Scott AM, Reilly EB.

Mol Cancer Ther. 2018 Apr;17(4):795-805. doi: 10.1158/1535-7163.MCT-17-0710. Epub 2018 Feb 26.

5.

A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.

Vaidya KS, Oleksijew A, Tucker LA, Pappano WN, Anderson MG, Grinnell CM, Zhang Q, Heighton SJ, Mitten MJ, Mishra S, Palma JP, Wang J, Reilly EB, Boghaert ER.

Pharmacology. 2017;100(5-6):229-242. doi: 10.1159/000478663. Epub 2017 Jul 26.

PMID:
28743107
6.

ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.

Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP, Naumovski L, Reilly EB.

Clin Cancer Res. 2017 Feb 15;23(4):992-1000. doi: 10.1158/1078-0432.CCR-16-1568. Epub 2016 Aug 29.

7.

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.

Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya KS, Oleksijew A, Boghaert E, Song M, Sokolova I, Pestova E, Anderson M, Pappano WN, Ansell P, Bhathena A, Naumovski L, Corvaia N, Reilly EB.

BMC Cancer. 2016 Feb 16;16:105. doi: 10.1186/s12885-016-2138-z.

8.

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.

Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG, McKay LM, Goodwin NC, Reilly EB.

Mol Cancer Ther. 2016 Apr;15(4):661-9. doi: 10.1158/1535-7163.MCT-15-0901. Epub 2016 Feb 4.

9.

A phase 1 study of ABT-806 in subjects with advanced solid tumors.

Cleary JM, Reardon DA, Azad N, Gandhi L, Shapiro GI, Chaves J, Pedersen M, Ansell P, Ames W, Xiong H, Munasinghe W, Dudley M, Reilly EB, Holen K, Humerickhouse R.

Invest New Drugs. 2015 Jun;33(3):671-8. doi: 10.1007/s10637-015-0234-6. Epub 2015 Apr 17.

PMID:
25895099
10.

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.

Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, Gu J, Digiammarino EL, Palma JP, Donawho CK, Goodwin NC, Scott AM.

Mol Cancer Ther. 2015 May;14(5):1141-51. doi: 10.1158/1535-7163.MCT-14-0820. Epub 2015 Mar 2.

11.

The potency of erythropoietin-mimic antibodies correlates inversely with affinity.

Lacy SE, DeVries PJ, Xie N, Fung E, Lesniewski RR, Reilly EB.

J Immunol. 2008 Jul 15;181(2):1282-7.

12.

A potent erythropoietin-mimicking human antibody interacts through a novel binding site.

Liu Z, Stoll VS, Devries PJ, Jakob CG, Xie N, Simmer RL, Lacy SE, Egan DA, Harlan JE, Lesniewski RR, Reilly EB.

Blood. 2007 Oct 1;110(7):2408-13. Epub 2007 Jul 9.

13.

Amino-substituted heterocycles as isosteres of trans-cinnamides: design and synthesis of heterocyclic biaryl sulfides as potent antagonists of LFA-1/ICAM-1 binding.

Wang GT, Wang S, Gentles R, Sowin T, Leitza S, Reilly EB, von Geldern TW.

Bioorg Med Chem Lett. 2005 Jan 3;15(1):195-201.

PMID:
15582439
14.

Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 4. Structure-activity relationship of substituents on the benzene ring of the cinnamide.

Winn M, Reilly EB, Liu G, Huth JR, Jae HS, Freeman J, Pei Z, Xin Z, Lynch J, Kester J, von Geldern TW, Leitza S, DeVries P, Dickinson R, Mussatto D, Okasinski GF.

J Med Chem. 2001 Dec 6;44(25):4393-403.

PMID:
11728185
15.

Discovery of potent antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 3. Amide (C-ring) structure-activity relationship and improvement of overall properties of arylthio cinnamides.

Pei Z, Xin Z, Liu G, Li Y, Reilly EB, Lubbers NL, Huth JR, Link JT, von Geldern TW, Cox BF, Leitza S, Gao Y, Marsh KC, DeVries P, Okasinski GF.

J Med Chem. 2001 Aug 30;44(18):2913-20.

PMID:
11520199
16.

Discovery and SAR of diarylsulfide cyclopropylamide LFA-1/ICAM-1 interaction antagonists.

Link JT, Sorensen B, Liu G, Pei Z, Reilly EB, Leitza S, Okasinski G.

Bioorg Med Chem Lett. 2001 Apr 23;11(8):973-6.

PMID:
11327603
17.

Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties.

Liu G, Huth JR, Olejniczak ET, Mendoza R, DeVries P, Leitza S, Reilly EB, Okasinski GF, Fesik SW, von Geldern TW.

J Med Chem. 2001 Apr 12;44(8):1202-10.

PMID:
11312920
18.

Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead.

Liu G, Link JT, Pei Z, Reilly EB, Leitza S, Nguyen B, Marsh KC, Okasinski GF, von Geldern TW, Ormes M, Fowler K, Gallatin M.

J Med Chem. 2000 Oct 19;43(21):4025-40.

PMID:
11052808
20.

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.

Gillies SD, Reilly EB, Lo KM, Reisfeld RA.

Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1428-32.

21.

GD3-reactive antibodies can inhibit the lysis of autologous tumor cells by tumor-infiltrating lymphocytes.

Reilly EB, Antognetti G.

Cancer Immunol Immunother. 1992;35(1):59-62.

PMID:
1611624
22.
23.

The use of microcapsules for high density growth of human tumor infiltrating lymphocytes and other immune reactive T cells.

Reilly EB, Antognetti G, Wesolowski JS Jr, Sakorafas P.

J Immunol Methods. 1990 Feb 9;126(2):273-9.

PMID:
2303732
24.

A safer blood supply.

Reilly EB.

West J Med. 1989 Aug;151(2):206. No abstract available.

25.

Serine esterase and hemolytic activity in human cloned cytotoxic T lymphocytes.

Ferguson WS, Verret CR, Reilly EB, Iannini MJ, Eisen HN.

J Exp Med. 1988 Feb 1;167(2):528-40.

26.

Tissue-specific expression of functionally rearranged lambda 1 Ig gene through a retrovirus vector.

Cone RD, Reilly EB, Eisen HN, Mulligan RC.

Science. 1987 May 22;236(4804):954-7.

PMID:
3107128
27.
28.

Lambda chains and genes in inbred mice.

Eisen HN, Reilly EB.

Annu Rev Immunol. 1985;3:337-65. Review. No abstract available.

PMID:
3933530
29.
30.

Frequency of lambda light chain subtypes in mouse antibodies to the 2,4-dinitrophenyl (DNP) group.

Liu T, Reilly EB, Zhang CB, Eisen HN.

Eur J Immunol. 1984 Jul;14(7):667-72.

PMID:
6430711
31.

Amino acid and nucleotide sequences of variable regions of mouse immunoglobulin light chains of the lambda 3-subtype.

Reilly EB, Reilly RM, Breyer RM, Sauer RT, Eisen HN.

J Immunol. 1984 Jul;133(1):471-5.

PMID:
6202790
32.

Restricted association of V and J-C gene segments for mouse lambda chains.

Reilly EB, Blomberg B, Imanishi-Kari T, Tonegawa S, Eisen HN.

Proc Natl Acad Sci U S A. 1984 Apr;81(8):2484-8.

33.

Lyt-1, Lyt-2, and Lyt-3 antigens.

Gottlieb PD, Reilly EB, Durda PJ, Niezgodka M.

Methods Enzymol. 1984;108:666-83. No abstract available.

PMID:
6084804
34.

Medical testing.

Reilly EB.

Arch Intern Med. 1983 Oct;143(10):2014-5. No abstract available.

PMID:
6625795
35.

Synthesis of lambda light chain subtypes by stimulated and unstimulated mouse B cells.

Onodera Y, Reilly EB, Eisen HN.

Eur J Immunol. 1983 Sep;13(9):739-46.

PMID:
6413226
36.

Quantitative of anti-NP (4-hydroxy-3-nitrophenyl)-acetyl idiotype expression on spleen and thymus cells.

Wall KA, Frackelton AR Jr, Reilly EB, Azuma T, Chang TW, Eisen HN.

Eur J Immunol. 1983 Jun;13(6):441-8.

PMID:
6602707
37.

Synthesis of lambda 1, lambda 2, and lambda 3 light chains by mouse spleen B cells.

Reilly EB, Frackelton AR Jr, Eisen HN.

Eur J Immunol. 1982 Jul;12(7):552-7.

PMID:
6811287
38.

Pathology-epitomes of progress: clinical application of free cortisol estimation.

Reilly EB, Wong LG.

West J Med. 1982 May;136(5):425. No abstract available.

39.

Lyt-2 and Lyt-3 alloantigens: precipitation with monoclonal and conventional antibodies and analysis on one- and two-dimensional polyacrylamide gels.

Reilly EB, Auditore-Hargreaves K, Hämmerling U, Gottlieb PD.

J Immunol. 1980 Nov;125(5):2245-51. No abstract available.

PMID:
7430627
40.

Pathology-epitomes of progress: fine-needle aspiration biopsy cytology.

Yuja RE, Reilly EB.

West J Med. 1980 Apr;132(4):341. No abstract available.

41.

Studies of antigen-RNA and immunity.

Garvey JS, Reilly EB.

Mol Cell Biochem. 1979 Mar 5;24(1):45-62. Review. No abstract available.

PMID:
379590
42.

Biological and chemical characterization of an immune antigen-RNA species derived from hepatocyte polysomes.

Reilly EB, Garvey JS.

Cell Immunol. 1978 Nov;41(1):20-34. No abstract available.

PMID:
719767
43.

A comparison of the onset of bronchodilator activity of metaproterenol and isoproterenol aerosols.

Reilly EB, Rodgers JM, Bickerman HA.

Curr Ther Res Clin Exp. 1974 Aug;16(8):759-64. No abstract available.

PMID:
4217241
44.

The detection of cancer cells in the bone marrow.

Slager UT, Reilly EB.

Prog Clin Cancer. 1970;4:193-202. No abstract available.

PMID:
5416730
45.

Value of examining bone marrow in diagnosing malignancy.

Slager UT, Reilly EB.

Cancer. 1967 Aug;20(8):1215-20. No abstract available.

PMID:
6030990
46.

Higher safety standards increasing blood bank work load.

Reilly EB, Klein SJ, Slager UT.

Hospitals. 1967 Feb 16;41(4):65-6. No abstract available.

PMID:
6045040
47.

Survival of isogeneic male erythrocytes in female mice.

Massey BW, Maher JA, Klein SJ, Reilly EB.

Transplantation. 1966 May;4(3):329-32. No abstract available.

PMID:
6006707
48.

The neuropathology of barbiturate intoxication.

Slager UT, Reilly EB, Brandt RA.

J Neuropathol Exp Neurol. 1966 Apr;25(2):237-43. No abstract available.

PMID:
5949174
49.

Primary hemangioma of the skull. Case report of an unusual tumor.

Sargent EN, Reilly EB, Posnikoff J.

Am J Roentgenol Radium Ther Nucl Med. 1965 Dec;95(4):874-9. No abstract available.

PMID:
5215159
50.

Enhancement of immunofluorescent staining of erythrocytes by saponin hemolysis.

Massey BW, Klein SJ, Reilly EB.

Transfusion. 1965 Sep-Oct;5(5):434-9. No abstract available.

PMID:
5319060

Supplemental Content

Loading ...
Support Center